Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

被引：4

作者：

Garcia-Manero, Guillermo ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Santini, Valeria ^{[3
]}

Zeidan, Amer M. ^{[4
,5
]}

Fenaux, Pierre ^{[6
]}

Komrokji, Rami S. ^{[7
]}

Shortt, Jake ^{[8
,9
]}

Valcarcel, David ^{[10
]}

Jonasova, Anna ^{[11
]}

Dimicoli-Salazar, Sophie ^{[12
]}

Tiong, Ing Soo ^{[13
]}

Lin, Chien-Chin ^{[14
]}

Li, Jiahui ^{[15
]}

Zhang, Jennie ^{[15
]}

Giuseppi, Ana Carolina ^{[15
]}

Kreitz, Sandra ^{[16
]}

Pozharskaya, Veronika ^{[15
]}

Keeperman, Karen L. ^{[15
]}

Rose, Shelonitda ^{[15
]}

Prebet, Thomas ^{[15
]}

Degulys, Andrius ^{[17
,18
]}

Paolini, Stefania ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Della Porta, Matteo Giovanni ^{[21
,22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Leipzig, Med Ctr, Dept Hematol Cellular Therapy Hemostaseol & Infec, Leipzig, Germany

[3] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, DMSC, Florence, Italy

[4] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA

[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[6] Univ Paris 07, Hop St Louis, Paris, France

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Monash Univ, Melbourne, Australia

[9] Monash Hlth, Melbourne, Australia

[10] Hosp Univ Vall dHebron, Barcelona, Spain

[11] Charles Univ Prague, Gen Univ Hosp, Med Dept Hematol, Prague, Czech Republic

[12] Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France

[13] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Australia

[14] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Bristol Myers Squibb, Celgene Int Sarl, Boudry, Switzerland

[17] Vilnius Univ Hosp, Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania

[19] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy

[22] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 48 条

[21] Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment.
Garcia-Manero, Guillermo
Matsuno, Rayna K.
McBride, Ali
Brown, Thomas D.
Idryo, Danny
Broome, Ronda
Herriman, Autumn
Johnson, Tiffany
Wilkinson, Kristiana
Walters, Sheetal
Schrag, Andrew
Johanson, Colden
Izano, Monika A.
Mukherjee, Sudipto
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.
Fenaux, Pierre
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer Methqal
Garcia-Manero, Guillermo
Buckstein, Rena
Miteva, Dimana
Keeperman, Karen
Holot, Natalia
Zhang, Jennie
Hughes, Christina
Rosettani, Barbara
Yucel, Aylin
Platzbecker, Uwe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
Mukherjee, Sudipto
Brown-Bickerstaff, Cherrishe
Falkenstein, Angelica
Makinde, Adeola Y.
Bland, Emily
Laney, JaLyna
Garretson, Marne Prime
McBride, Ali
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Assessment of dose-dependent response to luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the phase 3 MEDALIST trial
Platzbecker, U.
Germing, U.
Goetze, K.
Heuser, M.
Thol, F.
Fenaux, P.
Komrokji, R. S.
Laadem, A.
Ito, R.
Zhang, J.
Rampersad, A.
Morison, J.
Louis, C. U.
Giagounidis, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
[25] Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), ErythropoiesisStimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Della Porta, Matteo Giovanni
Santini, Valeria
Zeidan, Amer M.
Komrokji, Rami S.
Li, Jiahui
Pilot, Richard
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Lai, Yinzhi
Valcarcel, David
Fenaux, Pierre
Platzbecker, Uwe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S388 - S388
[26] Longer-term RBC transfusion reduction in the phase 3 MEDALIST study of luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS)
Platzbecker, U.
Giagounidis, A.
Heuser, M.
Goetze, K.
Thol, F.
Fenaux, P.
Komrokji, R. S.
Laadem, A.
Ito, R.
Rampersad, A.
Zhang, J.
Louis, C. U.
Germing, U.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 169 - 169
[27] Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
Platzbecker, Uwe
Fenaux, Pierre
Mufti, Ghulam J.
Garcia-Manero, Guillermo
Komrokji, Rami S.
Buckstein, Rena
Diez-Campelo, Maria
Finelli, Carlo
Sekeres, Mikkael A.
Selleslag, Dominik
DeZern, Amy E.
Quesnel, Bruno
Beyne-Rauzy, Odile
Voso, Maria Teresa
Greenberg, Peter L.
Zeidan, Amer M.
Ades, Lionel
Verma, Amit
Savona, Michael R.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Morison, Jessica
Louis, Chrystal
Linde, Peter G.
Santini, Valeria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S318
[28] Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
Oliva, Esther Natalie
Platzbecker, Uwe
Porta, Matteo Giovanni Della
Garcia-Manero, Guillermo
Santini, Ualeria
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
Pelligra, Christopher G.
Guo, Shien
Yucel, Aylin
Glassberg, Mrudula B.
Eliason, Laurie
Hnoosh, Ahmed
Miteva, Dimana
Rose, Shelo
Santiri, Valeria
Kreitz, Sandra
Sekeres, Mikkael A.
Zeidan, Amer M.
BLOOD, 2024, 144 : 3217 - 3218
[29] Efficacy and Safety of Luspatercept plus /- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS- RS): A French Multicenter Prospective Real-Life Registry
Comont, Thibault
D'Aveni, Maud
Schenone, Laurence
Torregrosa-Diaz, Jose Miguel
Aguinaga, Lorea
Pardo, Juan
Sebert, Marie
Visanica, Sorin
Santana, Clemence
Le Clech, Lenaig
Stamatoullas, Aspasia
Thepot, Sylvain
Daguindau, Etienne
Beziat, Guillaume
Botin, Teresa
Dimicoli, Sophie
Park, Sophie
Paubelle, Etienne
Slama, Bohrane
Willems, Lise
Debarri, Houria
Gyan, Emmanuel
Calmettes, Claire
Rauzy, Odile
Chermat, Fatiha
Fontenay, Michaela
Ades, Lionel
Fenaux, Pierre
BLOOD, 2023, 142
[30] Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study
Platzbecker, Uwe
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer M.
Garcia-Manero, Guillermo
Buckstein, Rena J.
Rose, Shelonitda
Fabre, Shannon
Miteva, Dimana
Zhang, Jennie
Yucel, Aylin
Hughes, Christina
Fenaux, Pierre
BLOOD, 2021, 138

← 1 2 3 4 5 →